Overview
The traditional drug development process is costly, time-consuming, and fraught with high failure rates, often taking over a decade and billions of dollars to bring a new therapy to market. Despite advances in biotechnology, the complexity and vast volume of biological data remain a significant bottleneck, limiting the ability to efficiently identify promising drug candidates, predict clinical outcomes, and personalize treatments. How can we overcome these challenges and accelerate the journey from discovery to delivery?
Big data and data analytics are revolutionizing drug development by enabling faster discovery, reducing costs, and increasing precision—ultimately accelerating the delivery of life-saving therapies to patients and transforming healthcare as we know it. Join us to explore how this approach is shaping the future of medicine.
Schedule
Date: 20 Nov 2025, Thursday
Time: 3:30 PM - 6:30 PM (GMT +8:00) Kuala Lumpur, Singapore
Location: Guoco Midtown Network Hub (Level 2), 126 Beach Road, 189773
Speakers
Moderator's Profile:
Kenneth Goh, Associate Director Search & Evaluation, JLABS Singapore, Johnson & Johnson
Kenneth brings to J&J more than 10 years of diversified experience spanning academic research, clinical care, and commercial strategy. His industry experience and insights will help JLABS Singapore and our companies bridge the gap between scientific discovery and healthcare solutions to medical professionals and patients, as well as expand our outreach into the medical community in the region. Kenneth previously worked as a consultant with Bain & Company in its Singapore office, managing projects for pharma and medtech clients with the Healthcare and Life Sciences practice. He also spent five years working at Singapore General Hospital, mainly focused on clinical diagnostics for infectious disease. For his contributions during the COVID-19 pandemic, he received the COVID-19 Resilience Medal in 2023.
Speaker's Profile:
Yeva Shan, Director, External Innovation, R&D Data Science & Digital Health, Johnson & Johnson Innovative Medicine
Yeva Shan, Ph.D., is Director of External Innovation at Johnson & Johnson’s R&D Data Science & Digital Health team. She leads initiatives in AI/ML-driven target discovery, predictive biology, and GenAI-powered science, building strategic partnerships across startups, academia, and technology companies. Yeva holds a Ph.D. in Molecular Biology and brings experience in tech transfer, venture capital fund management, and management consulting. Her research has resulted in over 20 publications featured in leading journals, including Nature Medicine, Science, and Annual Review of Medicine.
Speaker's Profile:
Pauline Tay, Director, National Health Innovation Centre
Pauline leads the National Health Innovation Centre (NHIC) as Director, facilitating the innovation, development, commercialisation and adoption of health technologies at public hospital clusters in Singapore. Prior to this, she helmed the Innovation and Enterprise Directorate at the National Research Foundation of the Prime Minister’s Office, developing key signatures in Singapore’s tech ecosystem, such as the Singapore Week of Innovation and Technology (SWITCH), SGInnovate, Deep Tech Venture Funds and Accelerators, international and public-private partnerships. Pauline has also served in industry as the Chairperson of Technology, Innovation and Productivity at the Singapore Business Federation, Executive Director and Head of Innovation Partnerships at UBS, and COO/CSO at Celligenics. Pauline is technically trained with a PhD in stem cell biology/regenerative medicine and spent 15 years at the Agency for Science, Technology and Research (A*STAR).
Speaker's Profile:
Sharon Chan, VP, JLABS Asia Pacific, Johnson & Johnson
As VP JLABS Asia Pacific, Sharon is responsible for setting and driving the long-term growth strategy and plan for JLABS in the region, which includes JLABS Korea, JLABS Singapore and JLABS Shanghai. She brings more than 20 years of diverse, international and life sciences experience from London, Shanghai, Beijing, Hong Kong and Singapore. She began her career with Sosei-Heptares and had previously served as a member of the Senior Leadership Team for Baxter responsible for Asia Pacific Business Development. Prior to joining J&J, Sharon was Head of Asia at Aeras, where she established its Beijing office for the Bill & Melinda Gates Foundation. In 2020, Sharon was recognized by Forbes China as one of the 50 Top Women in Science & Technology. In 2021, Sharon was given a Social Impact Leadership Award Honoree by Serica.
Speaker's Profile:
John Chambers, Professor, Cardiovascular Epidemiology & Director, Health Screening Centre, Lee Kong Chian School of Medicine and Chief Scientific Officer, PRECISE, Lee Kong Chian School of Medicine & PRECISE
Professor Chambers is the Chief Scientific Officer (CSO) of PRECISE, the central entity established to implement Phase II of Singapore’s National Precision Medicine strategy. Prof Chambers is also the lead investigator of the PRECISE-SG100K population cohort study, a multi-institutional effort that aims to study the genetic makeup of 100,000 healthy Singaporeans and specific disease cohorts. The genetic data will be integrated with detailed lifestyle, environmental, and clinical data to yield rich insights into factors that contribute to Asian diseases and conditions. John is also Distinguished Professor of Cardiovascular Epidemiology at LKCMedicine, where he leads research focused on identification of mechanisms underlying the high rate of cardiovascular disease and diabetes in Asian populations, along with clinical translation to improve prevention and control of these major diseases.
Speaker's Profile:
Neil Deramchi, Principal, Tachyon Ventures
Neil Deramchi is a Principal at Tachyon Ventures, a science-native venture firm focused on AI-native biotech and platform therapeutics. At Tachyon, she leads diligence, portfolio strategy, and investment execution across computational biology, synthetic biology, and next-gen therapeutics. Previously, she was Director of Strategy at a Los Angeles-based private equity firm and is also a product strategist for several deep tech and AI companies. A biochemist by training, she holds a BSc from UCLA and an MSc in Biotechnology from USC.
Speaker's Profile:
Xiaoxue Wang, Co-founder & VP of AI, ChemLex
Dr. Xiaoxue Wang received her B.S. in Chemical Engineering from Tsinghua University, Beijing, China in 2012, and her Ph.D. degree in Chemical Engineering from Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts, USA in 2018 with a minor in Electrical Engineering. She is the co-founder and vice president of ChemLex Technology Co., Ltd., Shanghai, China, a company pioneering AI-driven autonomous chemical synthesis. At ChemLex, she leads a multidisciplinary team of AI researchers, operations researchers, chemical engineers, computational chemists, data engineers and software engineers to develop the AI system and data/IT infrastructure enabling self-driving laboratories.
Partners
